Mechanisms of common fragile site instability
Department of Human Genetics, University of Michigan, Ann Arbor, MI, USA
* To whom correspondence should be addressed at: Department of Human Genetics, University of Michigan, 4909 Buhl, PO Box 0618, 1241 E. Catherine Street, Ann Arbor, MI 48109-0618, USA. Tel: +1 7347635222; Fax: +1 7347633784; Email: glover{at}umich.edu
Received July 6, 2005; Accepted July 14, 2005
| ABSTRACT |
|---|
|
|
|---|
The study of common fragile sites has its roots in the early cytogenetic investigations of the fragile X syndrome. Long considered an interesting component of chromosome structure, common fragile sites have taken on novel significance as regions of the genome that are particularly sensitive to certain forms of replication stress, which are frequently rearranged in cancer cells. In recent years, much has been learned about the genomic structure at fragile sites and the cellular checkpoint functions that monitor their stability. Recent findings suggest that common fragile sites may serve as markers of chromosome damage caused by replication stress during early stages of tumorigenesis. Thus, the study of common fragile sites can provide insight not only into the nature of fragile sites, but also into the broader consequences of replication stress on DNA damage and cancer. However, despite recent advances, many questions remain regarding the normal functional significance of these conserved regions and the basis of their fragility.
| INTRODUCTION |
|---|
|
|
|---|
Common fragile sites are chromosomal regions that are particularly sensitive to forming gaps or breaks on metaphase chromosomes after partial inhibition of DNA synthesis (Fig. 1). These lesions were first seen in cells grown under conditions of folate stress used to induce cytogenetic expression of the fragile X site (FRAXA) in individuals with fragile X-linked mental retardation. It was later found that these fragile sites are also specifically induced by aphidicolin, an inhibitor of DNA polymerase
and other polymerases. Fragile sites are now generally categorized into two main classes. Rare fragile sites, such as the fragile X site, are seen in few individuals, are associated with CGG or AT repeat expansion mutations and segregate in a Mendelian manner (1
|
At present, 84 common fragile sites are listed in the genome database (GDB). The exact number of common fragile sites that exist is a matter of interpretation based on the criteria for inclusion and statistical analyses of data. The greater the stress placed on DNA replication, the more fragile sites are observed, until replication ceases. However, not all fragile sites form breaks at the same frequency, and a small number of sites in the genome are most prone to form lesions (3
| FRAGILE SITES ARE UNSTABLE IN VITRO |
|---|
|
|
|---|
Common fragile site regions are normally stable in cultured human cells. However, when cells are cultured under conditions of folate or thymidylate stress or with low doses of aphidicolin that only partially inhibit DNA synthesis, common fragile site regions form chromosome gaps and breaks. Other inhibitors of replication, such as hydroxyurea, are less specific in inducing lesions primarily at fragile sites, probably due to differences in mechanisms of inhibition.
In addition to gaps and breaks, common fragile sites display a number of characteristics of unstable DNA in cultured cells. Following induction, they are hotspots for increased sister chromatid exchange (SCE) (5
) and show a high rate of translocations and deletions in somatic cell hybrid systems (6
,7
). Rassool et al. (8
) demonstrated that fragile sites are preferred sites of recombination, or integration, with pSV2neo-plasmid DNA transfected into cells pretreated with aphidicolin. Perhaps related to this characteristic are reports of the coincidence of viral integration sites in tumors or tumor cell lines and fragile sites (9
12
). Fragile sites have also been implicated in intrachromosomal gene amplification events in cultured Chinese hamster ovary (CHO) cells and in cancer cells by leading to DNA strand breaks that trigger breakagefusionbridge cycles (13
).
| GENES AT COMMON FRAGILE SITES |
|---|
|
|
|---|
Eleven common fragile sites, FRA2G, FRA3B, FRA4F, FRA6E, FRA6F, FRA7E, FRA7G, FRA7H, FRA9E, FRA16D and FRAXB, have been cloned and characterized. All have been found to extend over hundreds of kilobases as defined by the induction of gaps or breaks on metaphase chromosomes occurring throughout these regions. As might be predicted given their size, most sites either lie within or span known genes (Table 1). FRA3B was the first fragile site to be mapped and cloned and it was found to lie within the FHIT gene (14
900 kb and includes two large introns where FRA3B is centrally located, but encodes only a small 1.1 kb transcript. There are no large di- or trinucleotide repeats within FRA3B, but the region was found to contain human cervical cancer HPV-16 integration sites (9
|
Two other of the most frequently expressed fragile sites also lie within large genes. FRA16D lies within the large WWOX gene, and like FHIT, WWOX encodes a small 2.2 kb transcript but extends >1 Mb due to the presence of two very large introns (18
3 kilobase transcript. The significance of the relationship of fragile sites to large genes is intriguing and could be a reflection of the base composition of large introns found in these genes. | FRAGILE SITES ARE EVOLUTIONARILY CONSERVED |
|---|
|
|
|---|
Common fragile sites have been observed in several other mammalian species, including other primates, cat, dog, pig, horse, cow, Indian mole rat, deer mouse and laboratory mouse (22
Studies from two laboratories suggest that there may also be fragile sites in Saccharomyces cerevisiae. Cha and Kleckner (34
) reported that yeast Mec1-deficiency results in global replication fork stalling, followed by non-random double-strand breaks (DSBs) that occur late in the S/G2-phase. These sites of breakage occur in regions that replicate slowly, called replication slow zones. Lemoine et al. (35
) created yeast mutants with reduced DNA polymerase
and found increased chromosome translocations and loss. The translocation breakage sites were non-random, with a preferred site located at a pair of Ty elements on chromosome III. Although their size and distribution indicate a more simple structure, these two reported classes of unstable regions in yeast may be functionally analogous to mammalian common fragile sites and could provide unique models for understanding fragile site instability and function.
| SEQUENCES AND FLEXIBILITY PEAKS AT FRAGILE SITES |
|---|
|
|
|---|
Sequence analyses of cloned fragile sites did not readily reveal why these sites are unstable. All fragile sites cloned to date are relatively AT-rich (18
| FRAGILE SITES ARE LATE REPLICATING |
|---|
|
|
|---|
Late replication is a feature of the rare fragile sites, as first shown for the fragile X site in FMR1 and later for FRAXE, FRA16B and FRA10B (41
Late replication is also a feature of the common fragile sites. Le Beau et al. (49
) were the first to show that sequences at FRA3B replicate very late and that the addition of aphidicolin resulted in a further significant delay in replication. Perhaps even more noteworthy is the finding that
16.5% of FRA3B sites remained unreplicated in G2 after the addition of aphidicolin. Replication timing studies of common fragile sites, FRA16D and FRA7H, indicate that these fragile sites also may experience difficulty in replication fork progression (50
,51
). These studies support a model in which common fragile site regions can initiate replication in early-mid S-phase but are slow to complete replication, and the chromosomal breaks and gaps observed in metaphase cells result from unreplicated DNA (50
). A high-resolution investigation of replication is needed to more clearly define the timing of origin firing and replication fork progression in fragile site regions. As other regions in the genome also replicate late, this feature alone does not define a fragile site. However, it is clear that late-replicating DNA in fragile site regions is particularly sensitive to further delay in response to replication inhibitors and as such play a role in fragile site instability.
| CELL-CYCLE CHECKPOINTS ACTIVELY MONITOR FRAGILE SITES |
|---|
|
|
|---|
Cells have evolved cell-cycle checkpoints to delay cell division in response to DNA lesions to allow for their repair. We have been interested in elucidating those mechanisms that recognize the fragile site lesions as a means of understanding the molecular nature of fragile sites and the cellular processes that affect their stability.
Based on the appearance of chromosome gaps and breaks at fragile sites and the methods used for their induction, the ATM and ATR kinases were primary candidates. ATM and ATR act in parallel, partially overlapping, checkpoint pathways in response to replication stress and DNA damage (52
,53
). ATM is activated primarily by DNA DSBs, such as those induced by ionizing irradiation (54
), whereas ATR responds primarily to replication stalling such as those caused by ultraviolet light, hydroxyurea, aphidicolin and hypoxia (55
58
). ATM signaling can activate the G1 and later checkpoints (52
). ATR functions during the intra-S and G2/M checkpoints to stabilize, and later restart, stalled replication forks (59
,60
), inhibit late origin firing in the presence of stresses (60
) and block cell-cycle progression into mitosis before replication is complete (57
).
Casper et al. (61
) have studied the effects of ATM and ATR on fragile site stability. No significant difference was found between ATM-deficient cells and normal control cells in spontaneous or aphidicolin-induced chromosome gaps or breaks, or breaks at specific fragile sites. However, ATR-deficient cells were very sensitive to aphidicolin and showed a highly significant increase in gaps and breaks at fragile sites. Importantly, fragile sites were expressed in ATR-deficient cells even without the addition of replication inhibitors. Casper et al. (62
) also found that cells from individuals with Seckel syndrome that have hypomorphic mutations in ATR are sensitive to aphidicolin and show increased instability at common fragile sites. Thus, ATR is necessary for the maintenance of stability at fragile sites during normal cell divisions, as well as in cells with replication stress.
These results suggest that perturbed replication at fragile sites leads to ATR-dependent activation of cell-cycle checkpoints. Although the lack of increased fragile site expression in ATM-deficient cells suggests that DSBs are not the initial or primary cause of fragile site expression, the ATM pathway may be important in subsequent events at fragile sites, particularly in the resolution of DSBs that must sometimes occur at fragile sites in giving rise to chromosomal rearrangements. Given the overlapping functions of these two proteins, it is also possible that ATR can compensate for ATM deficiency with regard to fragile site stability, but not vice versa.
The ATR checkpoint was the first major pathway found to be associated with control of fragile site expression and this discovery was important in linking cell-cycle checkpoint function with fragile site stability. Subsequent investigations have focused on further delineation of these mechanisms, and a number of targets or modifiers of the ATR pathway have now been shown to influence fragile site stability, including BRCA1, the Fanconi anemia (FA) pathway proteins and SMC1.
BRCA1 has a number of important functions in the DNA damage response, including roles in checkpoint and repair processes. Arlt et al. (63
) showed that BRCA1 is important for the maintenance of fragile site stability, specifically via its G2/M checkpoint. This result is consistent with the late replication seen at fragile sites and points to a specific checkpoint involved in fragile site stability. These data do not rule out other functions of BRCA1, such as homologous repair (HR), in common fragile site stability, but it is clear that BRCA1 helps to activate the G2/M checkpoint in response to stalled replication via ATR-dependent phosphorylation of BRCA1 serine 1423 and other residues.
Howlett et al. (64
) have recently examined the role of the FA pathway in the maintenance of fragile site stability. Several lines of evidence had suggested a role for the FA pathway in the response to DNA replication stress and in the maintenance of fragile site stability. The FANCD2 protein is activated via mono-ubiquitination (mono-Ub) during S-phase, signaling its translocation to BRCA1- and RAD51-positive nuclear foci (65
). It had also been shown that ATR phosphorylates FANCD2 and is required for its efficient mono-Ub (66
). The FA pathway was found to be strongly activated by aphidicolin and disruption of the FA pathway resulted in a 35-fold increase in fragile site breaks. These results further support an important role for the FA pathway in the ATR-dependent replication stress response and also demonstrated a role in the maintenance of fragile site stability.
More recently, Musio et al. (67
) reported that SMC1 deficiency increases breakage at fragile sites. SMC1 is a member of the structural maintenance of chromosomes protein family, whose members play important roles in chromosome condensation, sister chromatid cohesion and DNA repair (68
). SMC1 forms a heterodimer with SMC3 to form the core of the cohesin complex. It is also a direct target of ATM phosphorylation after IR (69
) and was shown by Musio et al. (67
) to be phosphorylated in response to aphidicolin. This phosphorylation does not affect binding to chromatin or to SMC3 (70
), but is required for S-phase checkpoint activity (71
). Further studies on the relationship of SMC proteins to fragile site instability and repair should better define this relationship.
Replication is routinely arrested by a variety of stresses, and checkpoint recognition and the associated repair of these sites are essential for genome maintenance. Currently, much more is known about the checkpoint and repair responses to DNA DSBs than to stalled replication due to replication inhibition. Most studies of these checkpoint and repair pathways have used high concentrations of replication inhibitors, such as aphidicolin and hydroxyurea, which would normally completely block replication. Fragile sites are induced at much lower concentrations that only partially inhibit replication and that may be more relevant to natural genotoxic exposure levels. Thus, fragile sites provide a novel cytological assay to help further delineate these checkpoints and associated DNA repair pathways in mammalian cells.
| DNA REPAIR AT FRAGILE SITES |
|---|
|
|
|---|
Little is known about how lesions at fragile sites are repaired. Most studies of repair responses have focused on DNA DSBs, whereas little is known about the repair of stalled replication forks or lesions resulting from replication stress that occur at fragile sites. HR plays the major role in responding to DSBs and stalled or collapsed replication forks during S and G2, when the sister chromatid is present. Interestingly, Glover and Stein (5
| FRAGILE SITE INSTABILITY IN TUMOR CELLS |
|---|
|
|
|---|
A number of early fragile site studies attempted to correlate the location of fragile sites with the sites of frequent chromosome breaks and rearrangements in cancers. These attempts were hampered by the large number of both fragile sites and chromosome breakpoints in tumors and the relatively low resolution of banded chromosomes. However, with the cloning of fragile sites, numerous studies have shown that common fragile sites are unstable in tumor cells, albeit not necessarily in the ways originally proposed.
Most such studies have focused on FRA3B and FRA16D due to the fact that they are the two most frequently expressed and best-characterized fragile sites, and both lie within large tumor suppressor genes. FRA3B frequently shows allelic loss or homozygous deletions in many tumor types including lung, digestive tract, kidney and breast (79
81
). The rearrangements are usually one or more large deletions of tens to hundreds of kilobases directly within the fragile site region. Investigation of chromosome 3 homologs from tumor cell lines showed multiple variable deletions within FRA3B, thus suggesting ongoing instability in the region (82
). Only a few translocations with breakpoints in FRA3B have been reported (83
85
). Whether this represents a form of ascertainment bias or is a true reflection of the frequency of translocations at fragile sites is not known. The deletions at FRA3B inactivate the FHIT gene, and partly based on these deletions, FHIT was suggested to be a tumor suppressor gene. More recent functional studies strengthen this hypothesis. FHIT-deficient mice have increased NMBA-induced gastric tumors (86
) and this susceptibility can be rescued by the introduction of a functional FHIT allele. In addition, overexpression of FHIT has been shown to suppress the growth of different cancer cell lines both in vitro and in vivo (87
). Thus, loss of FHIT appears to play a role in mutagen sensitivity and cancer susceptibility.
FRA16D maps within regions of frequent loss-of-heterozygosity (LOH) in breast and prostate cancers and is associated with homozygous deletions in various adenocarcinomas and with chromosomal translocations in multiple myeloma. These rearrangements inactivate the WWOX gene, which is defined as a tumor suppressor gene by the virtue of these large, intragenic, homozygous deletions and point mutations in cancers and its ability to suppress the growth of mammary tumors in mice, possibly via a role in apoptosis pathways (18
,88
91
). Similar patterns of deletions in cancer cells have also been shown for other common fragile sites including FRA6E (20
), FRA9E (92
) and FRA7G (19
,93
).
It is clear from numerous studies that FRA3B, FRA16D and other common fragile sites contain large, intralocus deletions or translocations that frequently inactivate associated genes, such as FHIT and WWOX, in a variety of tumor cells (94
). The type of mutations primarily seen in these genes in tumors, large deletions and translocations, as opposed to point mutations, supports the involvement of the associated fragile sites in the mutations. This raises the important question of whether the deletions are simply a result of chromosome instability at fragile sites or the selection for cells with loss of gene function or a combination of both. A number of tumors have been identified with deletions in more than one fragile site, suggesting a common mechanism (38
,95
). In addition, fragile site instability in tumors appears not to be driven solely by associated genes, because FRAXB at Xp23.3 also shows frequent deletions in tumor cells, yet none of the genes identified at FRAXB is involved in tumor progression (38
). However, given the function of FHIT and WWOX in tumorigenesis, it seems likely that at least in some tumors, selection for loss of function driven by fragile site instability plays a role in tumor progression.
In addition to deletions, instability at fragile sites has also been implicated in gene amplification. Coquelle et al. (13
) have shown that breakage at fragile sites can initiate breakage fusionbridge cycles, a mechanism responsible for the accumulation of intrachromosomal amplicons, in drug-resistant mutant CHO cells. More recently, FRA7I and FRA7G have been identified at one boundary of the amplicons found in two tumor cell lines (96
). We recently characterized the boundaries of amplicons involving the MET oncogene in six primary esophageal adenocarcinomas (97
) and found that all have one boundary within FRA7G, consistent with the mechanisms proposed by Coquelle and co-workers.
Why are fragile site regions unstable in these tumor cells but not in normal cells? Casper et al. (61
) suggested that breaks at fragile sites may serve as signatures of stalled replication in tumor cells caused by mutations or perturbations of the S-phase and G2/M checkpoints or associated repair genes during tumor progression. Two recent reports support this concept and experimentally tie together what is known about the mechanisms leading to fragile site expression and chromosomal rearrangements at fragile sites in tumors. Gorgoulis et al. (98
) and Bartkova et al. (99
) examined bladder, breast, colorectal and lung tumors at various stages of progression for signs of a DNA damage response. Both found that early stages of cancer development, before malignancy, are associated with an active DNA damage response, including phosphorylated ATR, ATM, CHK1 and CHK2 kinases, and phosphorylated histone H2AX and p53. Concomitant with these events was a high frequency of LOH at known fragile site regions, including FRA3B. These findings suggest that in precancerous lesions, replication stress leads to stalled or collapsed replication forks, activation of the ATR and with subsequent DNA DSBs, the ATM checkpoints. In cells that do not undergo apoptosis or cell-cycle arrest, allelic imbalances will preferentially target fragile sites as they are most sensitive to replication stress. Further mutation in p53 or other genes will release additional checkpoints and lead to progression. These findings suggest that lesions at common fragile sites are indicators of replication stress during early stages of tumorigenesis. They are also consistent with a role for some fragile site-associated genes in cancer.
| A MODEL FOR COMMON FRAGILE SITES AND FUTURE DIRECTIONS |
|---|
|
|
|---|
Data from a number of laboratories support a model for common fragile sites. This model (Fig. 2) is based on late or delayed replication, unusual sequence composition and the role of checkpoint proteins in fragile site stability. It suggests that sequences at fragile sites present difficulties to replication, which are further exacerbated by aphidicolin and certain other forms of replication stress. Given that aphidicolin, an inhibitor of pol
, is the most specific inducer of common fragile sites, it is likely that lagging strand synthesis is centrally involved. A perturbation of lagging strand synthesis could result in the formation of unreplicated regions, and perhaps sequence-specific secondary structures (40
|
Thus, fragile site gaps are believed to represent unreplicated regions or single-stranded gaps on metaphase chromosomes. Deletions or translocations at fragile sites could result from DNA DSBs caused by the breakage of already weakened single-stranded regions or aberrant processing of Holliday junctions at damaged forks. Thus, the deletions seen in tumor cells are proposed to arise from unequal or faulty HR of stalled forks and would be enhanced by mutations in the replication checkpoint or associated repair pathways. In this way, deletions at fragile sites in tumor cells are signatures of replication stress.
Largely because of the identification of frequent fragile site instability in tumor cells and the link to important cell-cycle checkpoint pathways, the study of common fragile sites has become increasingly significant over the past few years, and a great deal has been learned about their genomic structure and mechanisms of instability. However, many questions remain. These include: Why are fragile site regions fragile? What are the dynamics of fragile site replication and repair? What forms of replication stress in vivo lead to frequent fragile site deletions in tumor cells? Do fragile sites have a conserved function, possibly one tied to cell-cycle progression? The answers to these and other questions are important to fully understand the normal functional significance of these conserved regions and the nature of their fragility in normal and cancer cells.
| ACKNOWLEDGEMENTS |
|---|
We thank Niall Howlett and Ryan Ragland for helpful discussions and Cynthia Gaffney for assistance. T.W.G. is supported by NIH grant CA43222.
Conflict of Interest statement. None declared.
| REFERENCES |
|---|
|
|
|---|
-
Kremer, E.J., Pritchard, M., Lynch, M., Yu, S., Holman, K., Baker, E., Warren, S.T., Schlessinger, D., Sutherland, G.R. and Richards, R.I. (1991) Mapping of DNA instability at the fragile X to a trinucleotide repeat sequence p(CCG)n. Science, 252, 17111714.
[Abstract/Free Full Text] - Sutherland, G.R., Baker, E. and Richards, R.I. (1998) Fragile sites still breaking. Trends Genet., 14, 501506.[CrossRef][ISI][Medline]
-
Glover, T.W., Berger, C., Coyle, J. and Echo, B. (1984) DNA polymerase
inhibition by aphidicolin induces gaps and breaks at common fragile sites in human chromosomes. Hum. Genet., 67, 136142.[CrossRef][ISI][Medline] -
Yunis, J.J. and Soreng, A.L. (1984) Constitutive fragile sites and cancer. Science, 226, 11991204.
[Abstract/Free Full Text] - Glover, T.W. and Stein, C.K. (1987) Induction of sister chromatid exchanges at common fragile sites. Am. J. Hum. Genet., 41, 882890.[ISI][Medline]
- Glover, T.W. and Stein, C.K. (1988) Chromosome breakage and recombination at fragile sites. Am. J. Hum. Genet., 43, 265273.[ISI][Medline]
- Wang, N.D., Testa, J.R. and Smith, D.I. (1993) Determination of the specificity of aphidicolin-induced breakage of the human 3p14.2 fragile site. Genomics, 17, 341347.[CrossRef][ISI][Medline]
-
Rassool, F.V., McKeithan, T.W., Neilly, M.E., van Melle, E., Espinosa, R., III and Le Beau, M.M. (1991) Preferential integration of marker DNA into the chromosomal fragile site at 3p14: an approach to cloning fragile sites. Proc. Natl Acad. Sci. USA, 88, 66576661.
[Abstract/Free Full Text] -
Wilke, C.M., Hall, B.K., Hoge, A., Paradee, W., Smith, D.I. and Glover, T.W. (1996) FRA3B extends over a broad region and contains a spontaneous HPV16 integration site: direct evidence for the coincidence of viral integration sites and fragile sites. Hum. Mol. Genet., 5, 187195.
[Abstract/Free Full Text] - De Braekeleer, M., Sreekantaiah, C. and Haas, O. (1992) Herpes simplex virus and human papillomavirus sites correlate with chromosomal breakpoints in human cervical carcinoma. Cancer Genet. Cytogenet., 59, 135137.[CrossRef][ISI][Medline]
- Popescu, N.C. and DiPaolo, J.A. (1989) Preferential sites for viral integration on mammalian genome. Cancer Genet. Cytogenet., 42, 157171.[CrossRef][ISI][Medline]
- Smith, P.P., Friedman, C., Bryant, E.M. and McDougall, J.K. (1992) Viral integration and fragile sites in human papillomavirus-immortalized human keratinocyte cell lines. Genes Chromosomes Cancer, 5, 150157.[ISI][Medline]
- Coquelle, A., Pipiras, E., Toledo, F., Buttin, G. and Debatisse, M. (1997) Expression of fragile sites triggers intrachromosomal mammalian gene amplification and sets boundaries to early amplicons. Cell, 89, 215225.[CrossRef][ISI][Medline]
- Wilke, C.M., Guo, S.W., Hall, B.K., Boldog, F., Gemmill, R.M., Chandrasekharappa, S.C., Barcroft, C.L., Drabkin, H.A. and Glover, T.W. (1994) Multicolor FISH mapping of YAC clones in 3p14 and identification of a YAC spanning both FRA3B and the t(3;8) associated with hereditary renal cell carcinoma. Genomics, 22, 319326.[CrossRef][ISI][Medline]
- Boldog, F.L., Waggoner, B., Glover, T.W., Chumakov, I., Le Paslier, D., Cohen, D., Gemmill, R.M. and Drabkin, H.A. (1994) Integrated YAC contig containing the 3p14.2 hereditary renal carcinoma 3;8 translocation breakpoint and the fragile site FRA3B. Genes Chromosomes Cancer, 11, 216221.[ISI][Medline]
- Ohta, M., Inoue, H., Cotticelli, M.G., Kastury, K., Baffa, R., Palazzo, J., Siprashvili, Z., Mori, M., McCue, P., Druck, T. et al. (1996) The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell, 84, 587597.[CrossRef][ISI][Medline]
-
Thorland, E.C., Myers, S.L., Persing, D.H., Sarkar, G., McGovern, R.M., Gostout, B.S. and Smith, D.I. (2000) Human papillomavirus type 16 integrations in cervical tumors frequently occur in common fragile sites. Cancer Res., 60, 59165921.
[Abstract/Free Full Text] -
Ried, K., Finnis, M., Hobson, L., Mangelsdorf, M., Sayan, S., Nancarrow, J.K., Woollatt, E., Kremmidiotis, G., Gardner, A., Venter, D. et al. (2000) Common chromosomal fragile site FRA16D sequence: identification of the FOR gene spanning FRA16D and homozygous deletions and translocation breakpoints in cancer cells. Hum. Mol. Genet., 9, 16511663.
[Abstract/Free Full Text] -
Bednarek, A.K., Laflin, K.J., Daniel, R.L., Liao, Q., Hawkins, K.A. and Aldaz, C.M. (2000) WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.324.1, a region frequently affected in breast cancer. Cancer Res., 60, 21402145.
[Abstract/Free Full Text] - Denison, S.R., Callahan, G., Becker, N.A., Phillips, L.A. and Smith, D.I. (2003) Characterization of FRA6E and its potential role in autosomal recessive juvenile parkinsonism and ovarian cancer. Genes Chromosomes Cancer, 38, 4052.[CrossRef][ISI][Medline]
- Rozier, L., El-Achkar, E., Apiou, F. and Debatisse, M. (2004) Characterization of a conserved aphidicolin-sensitive common fragile site at human 4q22 and mouse 6C1: possible association with an inherited disease and cancer. Oncogene, 23, 68726880.[CrossRef][ISI][Medline]
- Stone, D.M., Stephens, K.E. and Doles, J. (1993) Folate-sensitive and aphidicolin-inducible fragile sites are expressed in the genome of the domestic cat. Cancer Genet. Cytogenet., 65, 130134.[CrossRef][ISI][Medline]
- Stone, D.M., Jacky, P.B., Hancock, D.D. and Prieur, D.J. (1991) Chromosomal fragile site expression in dogs. Am. J. Med. Genet., 40, 214222.[CrossRef][ISI][Medline]
- Elder, F.F.B. and Robinson, T.J. (1989) Rodent fragile sites: are they conserved? Evidence from mouse and rat. Chromosoma, 97, 459464.[CrossRef][ISI][Medline]
- Smeets, D.F.C.M. and van de Klundert, F.A.J.M. (1990) Common fragile sites in man and three closely related primate species. Cytogenet. Cell Genet., 53, 814.[ISI][Medline]
- Yang, M.Y. and Long, S.E. (1993) Folate sensitive common fragile sites in chromosomes of the domestic pig (Sus scrofa). Res. Vet. Sci., 55, 231235.[ISI][Medline]
- McAllister, B.F. and Greenbaum, I.F. (1997) How common are common fragile sites: variation of aphidicolin-induced chromosomal fragile sites in a population of the deer mouse (Peromyscus maniculatus). Hum. Genet., 100, 182188.[CrossRef][ISI][Medline]
- Ruiz-Herrera, A., Garcia, F., Fronicke, L., Ponsa, M., Egozcue, J., Caldes, M.G. and Stanyon, R. (2004) Conservation of aphidicolin-induced fragile sites in Papionini (primates) species and humans. Chromosome Res., 12, 683690.[CrossRef][ISI][Medline]
- Soulie, J. and De Grouchy, J. (1981) A cytogenetic survey of 110 baboons (Papio cynocephalus). Am. J. Phys. Anthrop., 56, 107113.[CrossRef][ISI][Medline]
-
Glover, T.W., Hoge, A.W., Miller, D.E., Ascara-Wilke, J.E., Adam, A.N., Dagenais, S.L., Wilke, C.M., Dierick, H.A. and Beer, D.G. (1998) The murine Fhit gene is highly similar to its human orthologue and maps to a common fragile site region. Cancer Res., 58, 34093414.
[Abstract/Free Full Text] - Shiraishi, T., Druck, T., Mimori, K., Flomenberg, J., Berk, L., Alder, H., Miller, W., Huebner, K. and Croce, C.M. (2001) Sequence conservation at human and mouse orthologous common fragile regions, FRA3B/FHIT and Fra14A2/Fhit. Proc. Natl Acad. Sci. USA, 98, 57225727.
-
Matsuyama, A., Shiraishi, T., Trapasso, F., Kuroki, T., Alder, H., Mori, M., Huebner, K. and Croce, C.M. (2003) Fragile site orthologs FHIT/FRA3B and Fhit/Fra14A2: evolutionarily conserved but highly recombinogenic. Proc. Natl Acad. Sci. USA, 100, 1498814993.
[Abstract/Free Full Text] - Krummel, K.A., Denison, S.R., Calhoun, E., Phillips, L.A. and Smith, D.I. (2002) The common fragile site FRA16D and its associated gene WWOX are highly conserved in the mouse at Fra8E1. Genes Chromosomes Cancer, 34, 154167.[CrossRef][ISI][Medline]
-
Cha, R.S. and Kleckner, N. (2002) ATR homolog Mec1 promotes fork progression, thus averting breaks in replication slow zones. Science, 297, 602606.
[Abstract/Free Full Text] - Lemoine, F.J., Degtyareva, N.P., Lobcchev, K. and Petes, T.D. (2005) Chromosomal translocations in yeast induced by low levels of DNA polymerase a model for chromosome fragile sites. Cell, 120, 587598.[CrossRef][ISI][Medline]
-
Boldog, F., Gemmill, R., West, J., Robinson, M. and Li, E. (1997) Chromosome 3p14 homozygous deletions and sequence analysis of FRA3B. Hum. Mol. Genet., 6, 193203.
[Abstract/Free Full Text] -
Mishmar, D., Rahat, A., Scherer, S.W., Nyakatura, G., Hinzmann, B., Kohwi, Y., Mandel-Gutfroint, Y., Lee, J.R., Drescher, B., Sas, D.E. et al. (1998) Molecular characterization of a common fragile site (FRA7H) on human chromosome 7 by the cloning of a simian virus 40 integration site. Proc. Natl Acad. Sci. USA, 95, 81418146.
[Abstract/Free Full Text] - Arlt, M.F., Miller, D.E., Beer, D.G. and Glover, T.W. (2002) Molecular characterization of FRAXB and comparative common fragile site instability in cancer cells. Genes Chromosomes Cancer, 33, 8292.[CrossRef][ISI][Medline]
- Limongi, M.Z., Pelliccia, F. and Rocchi, A. (2003) Characterization of the human common fragile site FRA2G. Genomics, 81, 9397.[CrossRef][ISI][Medline]
-
Zlotorynski, E., Rahat, A., Sakaug, J., Ben-Porat, N., Ozeri, E., Herschberg, R., Levi, A., Scherer, S.W., Margalit, H. and Kerem, B. (2003) Molecular basis for expression of common and rare fragile sites. Mol. Cell. Biol., 23, 71437151.
[Abstract/Free Full Text] - Ohashi, H., Kuwano, A., Tsukahara, M., Arinami, T. and Kajii, T. (1990) Replication patterns of the fragile X in heterozygous carriers: analysis by a BrdUrd antibody method. Am. J. Hum. Genet., 47, 988993.[ISI][Medline]
- Yu, W.D., Wenger, S.L. and Steele, M.W. (1990) X chromosome imprinting in fragile X syndrome. Hum. Genet., 85, 590594.[ISI][Medline]
- Hansen, R.S., Canfield, T.K., Lamb, M.M., Gartler, S.M. and Laird, C.D. (1993) Association of fragile X syndrome with delayed replication of the FMR1 gene. Cell, 73, 14031409.[CrossRef][ISI][Medline]
-
Hansen, R.S., Canfield, T.K., Fjeld, A.D., Mumm, S., Laird, C.D. and Gartler, S.M. (1997) A variable domain of delayed replication in FRAXA fragile X chromosomes: X inactivation-like spread of late replication. Proc. Natl Acad. Sci. USA, 94, 45874592.
[Abstract/Free Full Text] - Subramanian, P.S., Nelson, D.L. and Chinault, A.C. (1996) Large domains of apparent delayed replication timing associated with triplet repeat expansion at FRAXA and FRAXE. Am. J. Hum. Genet., 59, 407416.
- Handt, O., Baker, E., Dayan, S., Gartler, S.M., Woollatt, E., Richards, R.I. and Hansen, R.S. (2000) Analysis of replication timing at the FRA10B and FRA16B fragile site loci. Chromosome Res., 8, 677688.[CrossRef][ISI][Medline]
-
Chen, X., Mariappan, S.V., Catasti, P., Ratliff, R., Moyzis, R.K., Laayoun, A., Smith, S.S., Bradbury, E.M. and Gupta, G. (1995) Hairpins are formed by the single DNA strands of the fragile X triplet repeats: structure and biological implications. Proc. Natl Acad. Sci. USA, 92, 51995203.
[Abstract/Free Full Text] - Hewett, D.R., Handt, O., Hobson, L., Mangelsdorf, M., Eyre, H.J., Baker, E., Sutherland, G.R., Schuffenhauer, S., Mao, J.I. and Richards, R.I. (1998) FRA10B structure reveals common elements in repeat expansion and chromosomal fragile site genesis. Mol. Cell, 1, 773781.[CrossRef][ISI][Medline]
-
Le Beau, M.M., Rassool, F.V., Neilly, M.E., Espinosa, R., III, Glover, T.W., Smith, D.I. and McKeithan, T.W. (1998) Replication of a common fragile site, FRA3B, occurs late in S phase and is delayed further upon induction: implications for the mechanism of fragile site induction. Hum. Mol. Genet., 7, 755761.
[Abstract/Free Full Text] - Palakodeti, A., Han, Y., Jiang, Y. and Le Beau, M.M. (2004) The role of late/slow replication of the FRA16D in common fragile site induction. Genes Chromosomes Cancer, 39, 7176.[CrossRef][ISI][Medline]
-
Hellman, A., Rahat, A., Scherer, S.W., Darvasi, A., Tsui, L.-C. and Kerem, S. (2000) Replication delay along FRA7H, a common fragile site on human chromosome 7, leads to chromosomal instability. Mol. Cell. Biol., 20, 44204427.
[Abstract/Free Full Text] -
Abraham, R.T. (2001) Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev., 15, 21772196.
[Free Full Text] - Durocher, D. and Jackson, S.P. (2001) DNA-PK, ATM and ATR as sensors of DNA damage: variations on a theme? Curr. Opin. Cell Biol., 13, 225231.[CrossRef][ISI][Medline]
-
Pincheira, J., Bravo, M., Navarrete, M.H., Marcelain, K., López-Sáez, J.F. and de la Torre, C. (2001) Ataxia telangiectasia: G2 checkpoint and chromosomal damage in proliferating lymphocytes. Mutagenesis, 16, 419422.
[Abstract/Free Full Text] - Cliby, W.A., Roberts, C.J., Cimprich, K.A., Stringer, C.M., Lamb, J.R., Schreiber, S.L. and Friend, S.H. (1998) Overexpression of a kinase-inactive ATR protein causes sensitivity to DNA-damaging agents and defects in cell cycle checkpoints. EMBO J., 17, 159169.[CrossRef][ISI][Medline]
-
Cortez, D., Guntuku, S., Qin, J. and Elledge, S.J. (2001) ATR and ATRIP: partners in checkpoint signaling. Science, 294, 17131716.
[Abstract/Free Full Text] -
Nghiem, P., Park, P.K., Kim, Y.-S., Vaziri, C. and Schreiber, S.L. (2001) ATR inhibition selectively sensitizes G1 checkpoint-deficient cells to lethal premature chromatin condensation. Proc. Natl Acad. Sci. USA, 98, 90929097.
[Abstract/Free Full Text] -
Hammond, E.M., Denko, N.C., Dorie, M.J., Abraham, R.T. and Giaccia, A.J. (2002) Hypoxia links ATR and p53 through replication arrest. Mol. Cell. Biol., 22, 18341843.
[Abstract/Free Full Text] - Lopes, M., Cotta-Ramusino, C., Pellicioli, A., Liberi, G., Plevani, P., Muzi-Falconi, M., Newlon, C.S. and Foiani, M. (2001) The DNA replication checkpoint response stabilizes stalled replication forks. Nature, 412, 557561.[CrossRef][Medline]
- Tercero, J.A. and Diffley, J.F.X. (2001) Regulation of DNA replication fork progression through damaged DNA by the Mec1/Rad53 checkpoint. Nature, 412, 553557.[CrossRef][Medline]
- Casper, A.M., Nghiem, P., Arlt, M.F. and Glover, T.W. (2002) ATR regulates fragile site stability. Cell, 111, 779789.[CrossRef][ISI]

